Search research articles
Contact Us
Filters
Showing results (41-50 of 50) with videos related to
Page
of 5
Sort By:
You have reached the last page of results.
This site can display upto 50 results.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 6, 2014
HIP1-ALK, a novel ALK fusion variant that responds to crizotinib
Douglas D Fang, Bin Zhang, Qingyang Gu, et al.
Blood
|
June 30, 2010
Enhanced c-Met activity promotes G-CSF-induced mobilization of hematopoietic progenitor cells via ROS signaling
Melania Tesio, Karin Golan, Simona Corso, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
May 31, 2011
Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification
Sai-Hong Ignatius Ou, Eunice L Kwak, Christina Siwak-Tapp, et al.
Science (New York, N.Y.)
|
April 28, 2007
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Jeffrey A Engelman, Kreshnik Zejnullahu, Tetsuya Mitsudomi, et al.
Plos One
|
July 5, 2013
Antitumor Efficacy of the Dual PI3K/mTOR Inhibitor PF-04691502 in a Human Xenograft Tumor Model Derived from Colorectal Cancer Stem Cells Harboring a PIK3CA Mutation
Douglas D Fang, Cathy C Zhang, Yin Gu, et al.
Journal of Medicinal Chemistry
|
August 29, 2012
Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (c-MET) protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (PF-04217903) for the treatment of cancer
J Jean Cui, Michele McTigue, Mitchell Nambu, et al.
Journal of Medicinal Chemistry
|
August 5, 2011
Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)
J Jean Cui, Michelle Tran-Dubé, Hong Shen, et al.
Journal of Medicinal Chemistry
|
May 5, 2012
Discovery of pyrroloaminopyrazoles as novel PAK inhibitors
Chuangxing Guo, Indrawan McAlpine, Junhu Zhang, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
January 24, 2009
KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients
Ketan S Gajiwala, Joe C Wu, James Christensen, et al.
JCI Insight
|
November 25, 2016
Institutional implementation of clinical tumor profiling on an unselected cancer population
Lynette M Sholl, Khanh Do, Priyanka Shivdasani, et al.
Page
of 5
Search research articles
Search
Showing results (41-50 of 50) with videos related to
Sort By:
Page
of 5
You have reached the last page of results.
This site can display upto 50 results.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 6, 2014
HIP1-ALK, a novel ALK fusion variant that responds to crizotinib
Douglas D Fang, Bin Zhang, Qingyang Gu, et al.
Blood
|
June 30, 2010
Enhanced c-Met activity promotes G-CSF-induced mobilization of hematopoietic progenitor cells via ROS signaling
Melania Tesio, Karin Golan, Simona Corso, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
May 31, 2011
Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification
Sai-Hong Ignatius Ou, Eunice L Kwak, Christina Siwak-Tapp, et al.
Science (New York, N.Y.)
|
April 28, 2007
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Jeffrey A Engelman, Kreshnik Zejnullahu, Tetsuya Mitsudomi, et al.
Plos One
|
July 5, 2013
Antitumor Efficacy of the Dual PI3K/mTOR Inhibitor PF-04691502 in a Human Xenograft Tumor Model Derived from Colorectal Cancer Stem Cells Harboring a PIK3CA Mutation
Douglas D Fang, Cathy C Zhang, Yin Gu, et al.
Journal of Medicinal Chemistry
|
August 29, 2012
Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (c-MET) protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (PF-04217903) for the treatment of cancer
J Jean Cui, Michele McTigue, Mitchell Nambu, et al.
Journal of Medicinal Chemistry
|
August 5, 2011
Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)
J Jean Cui, Michelle Tran-Dubé, Hong Shen, et al.
Journal of Medicinal Chemistry
|
May 5, 2012
Discovery of pyrroloaminopyrazoles as novel PAK inhibitors
Chuangxing Guo, Indrawan McAlpine, Junhu Zhang, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
January 24, 2009
KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients
Ketan S Gajiwala, Joe C Wu, James Christensen, et al.
JCI Insight
|
November 25, 2016
Institutional implementation of clinical tumor profiling on an unselected cancer population
Lynette M Sholl, Khanh Do, Priyanka Shivdasani, et al.
Page
of 5